These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 21361714)

  • 1. Adverse reactions following immunization with MMR vaccine in children at selected provinces of Iran.
    Esteghamati A; Keshtkar A; Heshmat R; Gouya MM; Salar Amoli M; Armin S; Mahoney F
    Arch Iran Med; 2011 Mar; 14(2):91-5. PubMed ID: 21361714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse events following immunisation associated with the 1998 Australian Measles Control Campaign.
    D'Souza RM; Campbell-Lloyd S; Isaacs D; Gold M; Burgess M; Turnbull F; O'Brien E
    Commun Dis Intell; 2000 Feb; 24(2):27-33. PubMed ID: 10758692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T; Baer M; Willems P
    Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse events associated with MMR vaccines in Japan.
    Kimura M; Kuno-Sakai H; Yamazaki S; Yamada A; Hishiyama M; Kamiya H; Ueda K; Murase T; Hirayama M; Oya A; Nozaki S; Murata R
    Acta Paediatr Jpn; 1996 Jun; 38(3):205-11. PubMed ID: 8741307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.
    Goh P; Lim FS; Han HH; Willems P
    Infection; 2007 Oct; 35(5):326-33. PubMed ID: 17710370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.
    Gillet Y; Steri GC; Behre U; Arsène JP; Lanse X; Helm K; Esposito S; Meister N; Desole MG; Douha M; Willems P
    Vaccine; 2009 Jan; 27(3):446-53. PubMed ID: 19007835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pediatric anaphylactic adverse events following immunization in Victoria, Australia from 2007 to 2013.
    Cheng DR; Perrett KP; Choo S; Danchin M; Buttery JP; Crawford NW
    Vaccine; 2015 Mar; 33(13):1602-7. PubMed ID: 25698493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative evaluation of measles, mumps & rubella vaccine at 9 & 15 months of age.
    Yadav S; Thukral R; Chakarvarti A
    Indian J Med Res; 2003 Nov; 118():183-6. PubMed ID: 14723482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life.
    Schuster V; Otto W; Maurer L; Tcherepnine P; Pfletschinger U; Kindler K; Soemantri P; Walther U; Macholdt U; Douha M; Pierson P; Willems P
    Pediatr Infect Dis J; 2008 Aug; 27(8):724-30. PubMed ID: 18600190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Studies on the safety and immunogenicity of lyophilized live attenuated measles-mumps-rubella combined vaccine].
    Liu G; Fang H; Feng Z; Guo W; Dong C; Zhang W; Ze W
    Zhonghua Liu Xing Bing Xue Za Zhi; 2002 Dec; 23(6):435-7. PubMed ID: 12667354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age.
    Halperin SA; Ferrera G; Scheifele D; Predy G; Stella G; Cuccia M; Douha M; Willems P
    Vaccine; 2009 May; 27(20):2701-6. PubMed ID: 19428882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of gender on reporting of MMR adverse events in Saudi Arabia.
    Khalil MK; Al-Mazrou YY; Al-Ghamdi YS; Tumsah S; Al-Jeffri M; Meshkhas A
    East Mediterr Health J; 2003; 9(1-2):152-8. PubMed ID: 15562745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of potentially common adverse events associated with the first and second doses of measles-mumps-rubella vaccine.
    LeBaron CW; Bi D; Sullivan BJ; Beck C; Gargiullo P
    Pediatrics; 2006 Oct; 118(4):1422-30. PubMed ID: 17015532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of measles-mumps-rubella, varicella and Haemophilus influenzae type b vaccines administered concurrently with a fourth dose of heptavalent pneumococcal conjugate vaccine compared with the vaccines administered without heptavalent pneumococcal conjugate vaccine.
    Black SB; Cimino CO; Hansen J; Lewis E; Ray P; Corsaro B; Graepel J; Laufer D
    Pediatr Infect Dis J; 2006 Apr; 25(4):306-11. PubMed ID: 16567981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measles-mumps-rubella revaccination; 18 months vs. 4-6 years of age: potential impacts of schedule changes.
    Saffar MJ; Fathpour GR; Parsaei MR; Ajami A; Khalilian AR; Shojaei J; Saffar H
    J Trop Pediatr; 2011 Oct; 57(5):347-51. PubMed ID: 21078605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of febrile convulsions after MMRV vaccination in comparison to MMR or MMR+V vaccination.
    Schink T; Holstiege J; Kowalzik F; Zepp F; Garbe E
    Vaccine; 2014 Feb; 32(6):645-50. PubMed ID: 24374498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age.
    Nolan T; Bernstein DI; Block SL; Hilty M; Keyserling HL; Marchant C; Marshall H; Richmond P; Yogev R; Cordova J; Cho I; Mendelman PM;
    Pediatrics; 2008 Mar; 121(3):508-16. PubMed ID: 18310199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of age on the risk of Fever and seizures following immunization with measles-containing vaccines in children.
    Rowhani-Rahbar A; Fireman B; Lewis E; Nordin J; Naleway A; Jacobsen SJ; Jackson LA; Tse A; Belongia EA; Hambidge SJ; Weintraub E; Baxter R; Klein NP
    JAMA Pediatr; 2013 Dec; 167(12):1111-7. PubMed ID: 24126936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
    Lieberman JM; Williams WR; Miller JM; Black S; Shinefield H; Henderson F; Marchant CD; Werzberger A; Halperin S; Hartzel J; Klopfer S; Schödel F; Kuter BJ;
    Pediatr Infect Dis J; 2006 Jul; 25(7):615-22. PubMed ID: 16804432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella.
    Nascimento Silva JR; Camacho LA; Siqueira MM; Freire Mde S; Castro YP; Maia Mde L; Yamamura AM; Martins RM; Leal Mde L;
    Vaccine; 2011 Aug; 29(37):6327-34. PubMed ID: 21640779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.